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Abstract
Limited data are available on the association between adiponectin and incident heart failure. In the
current ancillary study to the Physicians' Health Study, we used a prospective nested-case control
design to examine whether plasma adiponectin concentration was related to the risk of heart
failure. We selected 787 incident heart failure cases and 787 matched controls for the current
analysis. Each control was selected using a risk set sampling technique at the time of the
occurrence of the index case and matched on year of birth, age at blood collection, and race.
Adiponectin was measured using ELISA. Heart failure occurrence was self-reported in annual
follow-up questionnaire. Validation of self-reported heart failure in this cohort has been published.
The mean age was 58.7 years. In a conditional logistic regression adjusting for age, race, time of
blood collection, year of birth, hypertension, atrial fibrillation, smoking, alcohol intake, and
exercise, estimates of the relative risk (95% confidence interval) were 1.0 (ref), 0.74 (0.53–1.04),
0.67 (0.48–0.94), 0.70 (0.50–0.99), and 0.92 (0.65–1.30) from the lowest to the highest quintile of
adiponectin, respectively, p for quadratic trend 0.004. Additional adjustment for potential
mediating factors including diabetes, C-reactive protein, and body mass index led to the
attenuation of the estimate of effect [1.0 (ref), 0.81 (0.57–1.15), 0.75 (0.53–1.06), 0.83 (0.58–
1.18), and 1.26 (0.87–1.81) across consecutive quintiles of adiponectin]. Our data are consistent
with a J-shaped association between total adiponectin and the risk of heart failure among US male
physicians.
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Heart failure (HF) remains an important public health issue(1;2) and is associated with a
high mortality(3) despite improved medical and surgical management of HF. A large
proportion of HF cases is accounted for by antecedent coronary heart disease (CHD) and
Correspondence: Luc Djoussé, MD, MPH, ScD, FAHA Division of Aging, Brigham and Women's Hospital 1620 Tremont St, 3rd
floor; Boston MA 02120 Tel. (617) 525-7591, Fax. (617) 525-7739, ldjousse@rics.bwh.harvard.edu.
Author contribution: Study design (LD); Statistical analysis (LD, JBW); drafting the manuscript (LD); Heart failure adjudication
(LD and staff); laboratory assays (MT, NH); critical review of the manuscript (LD, NQH, MYT, JBW, RG, JMG); Obtaining funding
for this study (LD).
Disclosures: None
NIH Public Access
Author Manuscript
Obesity (Silver Spring). Author manuscript; available in PMC 2013 October 15.
Published in final edited form as:
Obesity (Silver Spring). 2013 April ; 21(4): 831–834. doi:10.1002/oby.20260.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
thypertension,(4–6) suggesting that predictors of CHD and hypertension might influence the
risk of HF. Adiposity is positively associated with HF risk(7;8) as well as its major risk
factors (diabetes(9), hypertension, and coronary artery disease(10–12)). Adipocytes express
several active hormones (including adiponectin) that influence cardiometabolic
factors(13;14) and subsequent risk of diabetes and CHD. Previous data have reported an
inverse association between measures of adiposity and plasma levels of adiponectin as well
as favorable effects of higher adiponectin levels on the risk of type 2 diabetes(15–17). In a
mouse model of myocardial infarction, adiponectin-knockout mice showed exacerbation of
left ventricular dilation, myocyte hypertrophy, and contractile dysfunction compared with
wild-type mice, 4 weeks after ligation of left anterior descending artery(18). In contrast,
administration of adiponectin to wild-type mice led to decreased left ventricular dilation and
interstitial fibrosis, improved left ventricular function, and diminished apoptosis(18). Other
experiments showed that adiponectin inhibits cardiac hypertrophic response to alpha-
adrenergic receptor stimulation(19). These data suggest that adiponectin may play a role in
the development of HF. However, limited studies have tested such a hypothesis in a
community setting among humans. Results from two previous prospective studies from
Framingham and Sweden showed no statistically significant association between plasma
adiponectin and incident HF. Whether these reported null findings from the above studies
were due to limited statistical power in each study or absence of a causal association
between adiponectin and HF risk remains unclear. Therefore, the current project sought to
assess the association between total plasma adiponectin and incident HF in a prospective
nested case-control study of US male physicians.
Methods
Study population
This is an ancillary study of the Physicians' Health Study I, which is a completed
randomized, double blind, placebo-controlled trial designed to study low-dose aspirin and
beta-carotene for the primary prevention of cardiovascular disease and cancer. A detailed
description of the PHS I has been published.(20) Current analyses used a prospective nested
case-control design to select subjects. Specifically, we limited our selection on PHS I
participants that provided blood samples between 1997 and 2001. For each case of HF, we
randomly selected a control among participants who were alive and free of HF at the time of
diagnosis of the index case and matched to the case on age at blood collection (within 2
years), race, year of birth (same), and time of blood collection (within 90 days). We have a
final sample of 822 pairs. Due to missing data on adiponectin on 35 subjects, current
analyses are based on 787 pairs. Each participant signed an informed consent and the
Institutional review Board at Brigham and Women's Hospital approved the study protocol.
Measurement of adiponectin
Adiponectin was measured using the Human Adiponectin Quantikine ELISA (R & D
Systems, Minneapolis, MN) at the University of Minnesota, Minneapolis, MN. The inter-
assay coefficient of variation was 5.5%.
Ascertainment of incident HF in the PHS
The ascertainment of endpoints including HF in the PHS has been achieved using yearly
follow-up questionnaires (except during the first year when each participant completed two
questionnaires six months apart) to obtain information on compliance with the intervention
and the occurrence of new outcomes including HF. Despite initial self-report of HF in this
cohort, we previously validated HF diagnosis in the PHS using the Framingham criteria(21)
on supplemental questionnaires in a subsample(22) as well as via chart review on limited
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tnumber of HF(23). Using these criteria, the positive predictive value of self-reported HF was
91% with excellent agreement between the 2 reviewers (kappa=92%).
Other variables
Demographic information was obtained through self-reports. At baseline, each subject
provided information on exercise [how often do you exercise vigorously enough to work up
sweat? Possible answers included rarely/never, 1–3/month, 1/week, 2–4/week, 5–6/week,
and daily]; smoking (never, former, and current smoker); and alcohol intake (rarely/never,
1–3 per month, 1 per week, 2–4/week, 5-5/week, daily, and 2+/day). Self-reported baseline
weight and height were used to compute body mass index (weight in kilograms divided by
height in meter squared). Data on comorbidity including hypertension, atrial fibrillation,
hyperlipidemia, and diabetes was collected at baseline and through follow-up
questionnaires.
Statistical analyses
We created quintiles of adiponectin using the distribution of adiponectin in the control
series. Means and percentages of baseline characteristics of the study participants are
presented according to quintiles of adiponectin. We used conditional logistic regression to
estimate the relative risk of HF using the lowest quintile of adiponectin as reference
category. The initial model adjusted for matching variables only (race, age, time of blood
collection, and year of birth). The final model additionally controlled for hypertension, atrial
fibrillation, cigarette smoking, alcohol consumption, and exercise. Missing data in some of
the covariates resulted in a loss of 26 matching pairs in the multivariable model. To obtain a
p value for linear trend, we created a new variable that was assigned the median value of
adiponectin in each quintile within the control series and fitted such a variable in the
conditional logistic regression. Similarly, to obtain p value for quadratic trend, we added a
squared term of the new variable in the above model. We assessed confounding using a 10%
estimate change. Lastly, we examined potential mediation by body mass index, diabetes, and
C-reactive protein by assessing whether their inclusion in the multivariable model would
lead to the attenuation of the relative risk. All analyses were performed using SAS (SAS
version 9.1, NC) and the alpha level was set at 0.05. All p values were 2-sided.
Results
Mean age among 1574 participants included in these analyses was 58.7 years (range 39.8 to
82.5) and median adiponectin was 7.41 μ g/ml (interquartile range 4.39 to 9.51). Baseline
characteristics according to the quintiles of total adiponectin are presented in Table 1.
Higher concentration of adiponectin was associated with older age, lower body mass index,
higher prevalence of alcohol consumption and physical activity, and lower prevalence of
diabetes, current smoking, and hypertension. In a conditional logistic regression, there was
evidence for an inverse association between total adiponectin and risk of heart failure. From
the lowest to the highest quintiles of adiponectin, relative risk for heart failure were 1.0 (ref),
0.74 (0.53–1.04), 0.67 (0.48–0.94), 0.70 (0.50–0.99), and 0.92 (0.65–1.30), respectively,
adjusting for matching factors, hypertension, atrial fibrillation, cigarette smoking, alcohol
consumption, and physical activity (Table 2). As expected, additional adjustment for
potential intermediate factors (body mass index, diabetes, hsCRP) attenuated the relative
risks (1.0 (ref), 0.81 (0.57–1.15), 0.75 (0.53–1.06), and 0.83 (0.58–1.18), and 1.26 (0.87–
1.81) across consecutive quintiles of total adiponectin).
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tDiscussion
In this prospective nested case-control study of apparently healthy male physicians, we
observed that after adjustment for potential confounding factors, total adiponectin was
inversely associated with heart failure risk in a non-linear fashion with the lowest risk
observed in the third quintile of total adiponectin.
While adiponectin has been inversely associated with CHD(24), adiponectin in patients with
established HF has been shown to predict higher mortality(25;26). However, few studies
have examined whether serum adiponection is associated with incident HF in community
settings. In a prospective study of 946 male subjects (70-year old), total adiponectin was not
associated with a statistically significant association with incident HF after an average
follow up of 9 years (crude HR=0.90 (95% CI: 0.72–1.13) per standard deviation of
adiponectin](27). These results are contrary to our findings of suggestive J-shaped
association of adiponectin to HF. The fact that Ingelsson et al(27) fitted adiponectin as a
linear term might have prevented the authors to observe a non-linear relationship. In
addition, it is reasonable to argue that myocardial infarction and insulin sensitivity could be
potential intermediate factors between adiponectin and HF; hence, adjustment for those
factors would attenuate any true relationship. Indeed, adjustment for body mass index,
diabetes, myocardial infarction, and hypertension completely eliminated the non-significant
association (HR: 1.09 (0.86–1.38) in the paper by Ingelsson and colleagues(27). Lastly, with
only 76 events, the authors lacked statistical power to detect a modest effect of adiponectin
on HF. Data from the Framingham Offspring study(28) (n=2739) reported 58 incident HF
after six years of follow up with age and sex adjusted hazard ratios of 1.0 (ref), 0.84 (0.45–
1.57), and 0.64 (0.32–1.27) across consecutive categories of adiponectin. In the Framingham
study(28), the wide confidence intervals around the point estimates suggest lack of precision
and point at low statistical power to detect any modest effect of adiponection on HF risk.
What biologic mechanisms could support a beneficial effect of adiponectin on the
development of HF? Elevated adiponectin levels have been shown to improve nitric oxide
production, reduce inflammation, apoptosis, improve insulin sensitivity, and left ventricular
systolic function(29). In animal experiments, hypoadiponectinemia in hypertension-induced
diastolic HF exacerbates left ventricular hypertrophy, diastolic dysfunction, and diastolic
HF(30). In addition, several studies have reported an inverse relation between adiponectin
and major risk factors of HF including adiposity(31), diabetes(31;32), myocardial
infarction(24), and hypertension(33;34). Could elevated concentrations of adiponectin carry
health risk? A U-shaped association between adiponectin and total mortality has been
reported(35). Furthermore, a non-linear relation between total and high-molecular weight
adiponectin with incident diabetes (a major risk factor for HF) was reported in older
adults(36). These data suggest that while moderate levels of adiponectin may be beneficial
for cardiovascular risk, it is possible that extremely higher concentrations of adiponectin
could be a direct response to homeostatic disregulation (i.e., underlying insulin resistance) or
inflammation. Such a hypothesis would be consistent with J- or U-shape association
between adiponectin and HF, diabetes, or mortality. At this point, we are unable to test such
a hypothesis and are relying on future studies for further elucidation.
Study strengths and limitations
The large number of participants, 22+ years of follow up, and the standardized methods of
endpoints ascertainment and measurement of adiponectin are major strengths of this study.
In addition, we were able to minimize confounding by age, race, time of blood collection,
and birth cohort effect through matching between each case and its corresponding control.
On the other hand, the fact that all participants were male physicians, most of whom were
Caucasians, limits the generalizabilty of the current findings. Furthermore, we did not have
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tdata on etiology or left ventricular systolic function to further subclassify HF. In the current
study, HF diagnosis was self-reported by participants; despite a 91% positive predictive
value of self-reported HF against validation via medical record review in a subsample and
the fact that participants were physicians, it is possible that self-report of HF may have led to
misclassification of HF. Such misclassification is more likely to be non-differential with
respect to adiponectin concentration and would likely have led to an underestimation of the
true effect. We did not have data on HF etiology and were not able to separate HF with
normal versus poor left ventricular ejection fraction. Lastly, this ancillary study could not
support the cost of biomarker measurement on all PHS I subjects. However, the fact that we
randomly selected control subjects using a risk set technique makes the findings
generalizable to the entire PHS I population.
In conclusion, our data showed a J-shaped association between total plasma adiponectin and
incident HF among US male physicians. Confirmation of these data in other populations is
warranted.
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Table 2
Relative risk (95% CI) of heart failure according to quintiles of total adiponectin
Relative risk (95% CI)
Quintiles of total adiponectin:
Median (range) in μ g/ml Cases Model 1* Model 2†
Q1(low) 3.17 (2.51–3.74) 209 1.00 1.00
Q2 5.09 (4.73–5.49) 143 0.67 (0.49–0.92) 0.74 (0.53–1.04)
Q3 6.68 (6.25–7.23) 131 0.61 (0.45–0.84) 0.67 (0.48–0.94)
Q4 8.81 (8.21–9.50) 140 0.65 (0.47–0.90) 0.70 (0.50–0.99)
Q5 (high) 12.91 (11.35–15.20) 164 0.75 (0.54–1.03) 0.92 (0.65–1.30)
P for quadratic trend 0.003 0.004
*
Model 1 adjusted for matching factors (age, race, time of blood collection, and year of birth)
†
Conditional logistic regression with additional adjustment for hypertension, atrial fibrillation, cigarette smoking, alcohol, and exercise (there was
a loss of 26 pairs due to missing covariates in Model 2).
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